Halozyme Therapeutics | HALO - 应收帐款人



金融业
股票价格
USD
资产
USD 2.58B
现金及等价物
USD 163.14M
销售成本
USD 108.68M
流动资产
USD 933.02M
流动负债
USD 344.44M
债务
USD 2.14B
EBIT
USD -63.72M
EBITDA
USD 328.81M
员工
350
EPS每股收益
USD 2.28
股本和储备
USD 143.54M
销售毛利
USD 297.47M
债务利息支出
USD 5.59M
贷款资金
USD 1.94B
市值
USD 13.89B
净收入
USD 229.91M
营业费用
USD 193.35M
营业利润
USD -63.72M
普通股股本
USD 114.04M
PE价格收益
12.51
税前利润
USD 180.33M
销售收入
USD 481M
销售和管理费用
USD 57M
股票
USD 137.14M
贸易债权人
USD 23.61M
应收帐款人
USD 453.33M


应收帐款人 更改 日
Acadia Pharmaceuticals USD 166.33M 17.95M 2026-06
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
Alnylam Pharmaceuticals USD 912.74M 28.78M 2026-06
Amarin USD 126.83M 477K 2025-12
Amgen USD 10.23B 1.09B 2026-06
Baxter International USD 1.86B 158M 2026-06
Cara Therapeutics USD 2.24M 2.26M 2025-03
Cytokinetics USD 6.83M 10.94M 2026-03
DBV Technologies USD 15.1M 1.05M 2026-03
Eli Lilly USD 23.48B 2.3B 2026-06
Halozyme Therapeutics USD 453.33M 4.66M 2026-06
Intrexon USD 1.02M 559K 2024-06
Ionis Pharmaceuticals USD 58.84M 15.16M 2026-06
MannKind USD 43.21M 15.07M 2026-06
Nektar Therapeutics USD 3.6M 1.82M 2026-03
Pfizer USD 16.19B 19M 2026-06
Rigel Pharmaceuticals USD 28.9M 1.39M 2024-06
United Therapeutics USD 310.3M 1.7M 2026-06
Vanda Pharmaceuticals USD 47.1M 4.35M 2024-12